Director Share Purchase

Kromek Group PLC

14 September 2026

 

14 September 2026

Kromek Group plc 

("Kromek", the "Company" or the "Group") 

Director Share Purchase

Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces that, on 14 September 2026, the wife of Rakesh Sharma, Non-executive Chairman of the Company, purchased 144,092 ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 6.94p per Ordinary Share.

Following this purchase, Mr. Sharma has an interest in 1,583,713 Ordinary Shares¹ in the Company, representing 0.2% of Kromek's issued share capital.

¹ Includes the holdings Mr. Sharma's wife

Enquiries 

Investor questions on this announcement
We encourage all investors to share questions on this announcement via our investor hub	https://investors.kromek.com/link/Pb6QoP
Kromek Group plc
Arnab Basu, CEO  Claire Burgess, CFO	[phone]
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance  Andrew Burdis - ECM Michael Johnson - Sales	[phone]
Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury	[phone]

Engage with the Kromek management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our interactive investor
hub here: https://investors.kromek.com/

Subscribe to our news alert service: https://investors.kromek.com/auth/signup

Kromek Group plc 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

 In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Kathleen Sharma
2	Reason for the notification
a)	Position/status	Wife of Rakesh Sharma, Non-executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Kromek Group plc
b)	LEI	213800VLHYXGHEX5VQ48
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 1 penny each
	Identification code	GB00BD7V5D43
b)	Nature of the transaction	Purchase of ordinary shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			6.94p	144,092
d)	Aggregated information -      Aggregated volume -      Price	N/A
e)	Date of the transaction	14 September 2026
f)	Place of the transaction	London Stock Exchange

 

END